Latest Safety News

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Paladin Energy reports a 33% production surge at its Langer Heinrich Mine alongside a key environmental milestone for its Canadian project and announces a new CEO appointment. The company outlines strong FY2026 guidance amid ongoing operational ramp-up.

Paladin Energy reported a 33% jump in uranium production at its Langer Heinrich Mine, alongside a major permitting milestone for its Canadian Patterson Lake South Project. Leadership changes and strong safety performance round out a quarter of significant progress.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Westgold Resources capped FY25 with record quarterly gold production and a $132 million treasury boost, while announcing a maiden 2.3 million ounce resource at its Fletcher Zone.

Magnetic Resources NL’s Feasibility Study confirms a robust standalone development for its Lady Julie Gold Project in Western Australia, projecting over 1 million ounces of gold production across nine years with strong financial returns.

Nico Resources Limited reported steady progress on its Wingellina nickel-cobalt project despite challenging market conditions, completing a $1.1 million share placement and advancing metallurgical and drilling programs.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.

Qoria Limited reported a robust 25% year-on-year growth in annual recurring revenue, hitting $145 million, alongside a 670% jump in EBITDA and a positive free cash flow outlook for FY2026. The company’s expanding global footprint and strategic partnerships underpin its strong momentum.

Metro Mining Limited has reported record Q2 shipments and site EBITDA margins, driven by a fully operational expansion and a robust bauxite market. Operational challenges from a tropical storm have been resolved, and exploration activities are accelerating.